Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer

Trial Information

Phase I Study of Vaccination With MPHOSHP1 and DEPDC1 Derived Epitope Peptides for HLA-A-24-positive Patients With Advanced Bladder Cancer

DEP domain containing 1(DEPDC1) and M phase phosphoprotein 1(MPHOSPH1) have been identified
using genome-wide expression profile analysis by the use of cDNA microarray in our previous
studies. We have determined the HLA-A*2402 restricted epitope peptides derived from DEPDC1,
DEPDC1-9-294, and MPHOSPH1, MPHOSPH1-9-278. These epitopes showed strong IFN-g production
when stimulated with the appropriate targets expressed the appropriate protein and
HLA-A*2402. Furthermore, when vaccinated these peptides, specific CTLs were determined
after the vaccination. Therefore we focused on the safety and efficacy of novel vaccination
for the advanced bladder cancer patients who already showed resistance to standard
chemotherapies or radiotherapy.

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.